---
title: "12 Health Care Stocks Moving In Thursday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292228111.md"
description: "During Thursday's intraday session, several healthcare stocks experienced significant volatility. Gainers included Virax Biolabs (VRAX) up 178.9%, Forte Biosciences (FBRX) up 55.48%, and First Tracks (TRAX) up 43.66%. Conversely, losers featured Ionis Pharmaceuticals (IONS) down 23.8%, AEON Biopharma (AEON) down 22.9%, and Tvardi Therapeutics (TVRD) down 22.4%."
datetime: "2026-07-09T17:05:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292228111.md)
  - [en](https://longbridge.com/en/news/292228111.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292228111.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's Intraday Session

### Gainers

-   **Virax Biolabs Group** (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million.
-   **Forte Biosciences** (NASDAQ:FBRX) stock rose 55.48% to $32.0. The market value of their outstanding shares is at $421.4 million.
-   **First Tracks** (NASDAQ:TRAX) shares rose 43.66% to $29.84. The market value of their outstanding shares is at $724.7 million.
-   **Circle8 Group** (NASDAQ:CIRC) stock moved upwards by 24.39% to $0.75. The company's market cap stands at $54.2 million.
-   **Evogene** (NASDAQ:EVGN) stock increased by 22.16% to $0.51. The market value of their outstanding shares is at $5.0 million.
-   **TransCode Therapeutics** (NASDAQ:RNAZ) shares moved upwards by 18.15% to $9.31. The company's market cap stands at $7.4 million.

### Losers

-   **Ionis Pharmaceuticals** (NASDAQ:IONS) shares declined by 23.8% to $64.33 during Thursday's regular session. The market value of their outstanding shares is at $13.9 billion.
-   **AEON Biopharma** (AMEX:AEON) shares decreased by 22.9% to $0.54. The market value of their outstanding shares is at $18.4 million.
-   **Tvardi Therapeutics** (NASDAQ:TVRD) shares fell 22.4% to $3.88. The market value of their outstanding shares is at $46.9 million.
-   **ABVC BioPharma** (NASDAQ:ABVC) stock declined by 20.89% to $1.6. The company's market cap stands at $52.5 million.
-   **ZeroStack** (NASDAQ:ZSTK) stock declined by 19.88% to $2.29. The company's market cap stands at $6.8 million.
-   **Catheter Precision** (AMEX:VTAK) shares declined by 17.16% to $1.14. The company's market cap stands at $4.9 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [VRAX.US](https://longbridge.com/en/quote/VRAX.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [AEON.US](https://longbridge.com/en/quote/AEON.US.md)
- [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md)
- [FBRX.US](https://longbridge.com/en/quote/FBRX.US.md)
- [TVRD.US](https://longbridge.com/en/quote/TVRD.US.md)
- [CIRC.US](https://longbridge.com/en/quote/CIRC.US.md)
- [EVGN.US](https://longbridge.com/en/quote/EVGN.US.md)
- [RNAZ.US](https://longbridge.com/en/quote/RNAZ.US.md)
- [ABVC.US](https://longbridge.com/en/quote/ABVC.US.md)
- [VTAK.US](https://longbridge.com/en/quote/VTAK.US.md)
- [34962G208.US](https://longbridge.com/en/quote/34962G208.US.md)

## Related News & Research

- [AEON Biopharma 10% owner Timothy P. Lynch buys 1,150,000 shares for $243,455](https://longbridge.com/en/news/296658850.md)
- [AEON Biopharma’s Timothy P. Lynch files initial beneficial ownership statement](https://longbridge.com/en/news/296658780.md)
- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [AEON Biopharma names former FDA neuroscience leader Paul Lee acting chief regulatory officer](https://longbridge.com/en/news/296784722.md)
- [AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended](https://longbridge.com/en/news/295705604.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**